Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Angel Yeast's Patented Probiotic S. boulardii Alleviates Common IBD Symptoms, New Research Shows

This image opens in the lightbox

News provided by

Angel Yeast

09 Feb, 2022, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

YICHANG, China, Feb. 9, 2022 /PRNewswire/ -- Angel Yeast Co., Ltd("Angel Yeast"), a listed global yeast and yeast extract manufacturer, has partnered with the Huazhong University of Science and Technology to conduct a clinical study that investigated the relationship between Saccharomyces boulardii Bld-3 (S. boulardii) and inflammatory bowel disease (IBD). The results of the study show that the patented yeast-based probiotic developed by Angel Yeast plays a beneficial role in addressing the symptoms of IBD.

Continue Reading
This image opens in the lightbox
Research shows that Angel Yeast's patented probiotic S. boulardii alleviates common IBD symptoms.

Data from the International Foundation for Gastrointestinal Disorders (IFGD) reveals that IBD is the most common functional gastrointestinal disorder and affects between 10-15% of the global population.[1] Typical medical treatments for IBD include antibodies, steroids and immunomodulators; however, these have low efficacy and a high incidence of recurrence.[2] As a result, there is a pressing need for innovative health therapeutics to help sufferers manage and treat the condition. S. boulardii was developed by Angel Yeast to address problems with diarrhea, one of the most common symptoms of IBD,[3] and improve overall digestive health.

Prior to the joint study, there was minimal research that examined the effects of S. boulardii and S. boulardii-derived molecules on the gut microbiota in intestinal inflammation. Gut microbiota has long been recognized as playing a pivotal role in maintaining the health of its host, with clinical data demonstrating that the gut microbiota of IBD patients varies considerably in composition and function.[4]

Angel Yeast partnered with Huazhong University of Science and Technology to explore the underlying mechanisms involved in the prevalence of IBD and identify the scientific relationship between S. boulardii and IBD. The duo examined the role of the probiotic in the gut microbial ecosystem and identified potential mechanisms of its intestinal anti-inflammatory activity.

In the study, [5] model organisms populated with synthetic human microbiota was given a diet of the S. boulardii probiotic supplement for a total of 16 days, before receiving DSS treatment to spur colitis. The results found that feeding subjects with S.boulardii significantly alleviated mucosal damage in colon tissue, altered the composition of gut microbiota and the fecal metabolic phenotype, and increased the development of microbial metabolite short-chain fatty acids. These findings point towards the probiotic's potential to improve the regulation of inflammatory responses and lessen DSS-induced colitis, and confirm S. boulardii has the potential to modulate the gut microbiota to successfully prevent and treat IBD. The findings were published in the Food & Function journal in November 2021.

Companies around the world have implemented Angel Yeast's S. boulardii patented probiotic into health supplements to meet the needs of consumers in search of a nutritional ingredient that supports overall immune health, good digestion and a happy, healthy gut. Now, following the new findings from the clinical study, S. boulardii has further demonstrated its potential to address IBD and support its sufferers by preventing and treating its symptoms.

Launched in September 2021, Angel Yeast's S. boulardii probiotic is developed using a low-temperature fluidized bed process and a unique protection technology that quickly forms a dense yeast shell to enclose active yeast probiotics entrapped inside. This strengthens the yeast's resistance to gastric acid and bile salts, enabling it to be used as an ingredient for wide-ranging probiotic dietary supplements, such as powders, tablets, capsules, yogurt blocks, and chocolate.

Sources:  

[1] International Foundation for Gastrointestinal Disorders (IFFGD).Statistics.  

[2]  Hvas CL et al., 2018. Current, Experimental, and Future Treatments in Inflammatory Bowel Disease: A Clinical Review, Immunopharmacology and Immunotoxicology, 40, 446-460. 

[3] World Gastroenterology Organisation Global Guidelines., 2015. Inflammatory Bowel Disease. 

[4] Lee T et al., 2017.Oral Versus Intravenous Iron Replacement Therapy Distinctly Alters the Gut Microbiota and Metabolome in Patients with Ibd, Gut, 66, 863-871.

[5] Li B et al., 2021. Saccharomyces boulardii alleviates DSS-induced intestinal barrier dysfunction and inflammation in humanized mice. Food & Function.

Photo - https://mma.prnewswire.com/media/1743158/image_1.jpg 
Logo - https://mma.prnewswire.com/media/1586948/angel_logo_Logo.jpg  

Modal title

Also from this source

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

Angel Yeast (SH:600298) a global leader in yeast manufacturing, has announced that its Baiyang Biotechnology Park ("the Park") located in the Yichang ...

Global Bakery Expo Spotlight: Angel Yeast Launches Feravor™ - A Revolutionary Natural Flavor Solution for Clean-Label Baking

Global Bakery Expo Spotlight: Angel Yeast Launches Feravor™ - A Revolutionary Natural Flavor Solution for Clean-Label Baking

At Europe's IBA 2025 and Asia's China Bakery Exhibition, Angel Yeast (SH600298) captured global attention with its groundbreaking Feravor™ series....

More Releases From This Source

Explore

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

Food & Beverages

Food & Beverages

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.